Jazz Pharmaceuticals and Boston Beer Company are featured in the Zacks Bull and Bear of the Day article.
These top medical stocks offer value and important services that investors might seek, especially as trade issues and global tensions begin to affect the markets.
Jazz (JAZZ) shares have begun to rise and could keep increasing soon, based on positive changes in earnings forecasts.
The average price target suggests that Jazz (JAZZ) could increase by 29.6%. Although studies indicate that this measure is not very reliable, an increase in earnings estimate revisions might indicate that the stock could rise soon.
Look into Jazz's (JAZZ) international revenue patterns and how these figures influence Wall Street's predictions and the future of the stock.
Jazz Pharmaceuticals finished 2024 positively, surpassing analyst predictions, although the revenue forecast for 2025 is a bit lower than expected. The postponement of the phase 3 trial results for zanidatamab is somewhat disappointing, but it might suggest a more favorable treatment outcome. I still view Jazz as a potential candidate for a valuation increase, supported by zanidatamab and Zepzelca, along with a return to growth and a decrease in perceived risks for the oxybate franchise.
Jazz has announced fourth-quarter results that are better than anticipated. Their new earnings per share (EPS) forecast for the full year 2025 is between $22.50 and $24.00, which is higher than what we expected.
The financial results for Jazz (JAZZ) provide an overview of the company's performance for the quarter ending in December 2024. It may be helpful to compare some important metrics with Wall Street predictions and figures from the same period last year.
Jazz Pharmaceuticals (JAZZ) reported quarterly earnings of $6.60 per share, which is higher than the Zacks Consensus Estimate of $5.79 per share. This is an increase compared to earnings of $5.02 per share from the same period last year.
Jazz (JAZZ) saw an increase in its share price during the last trading session, with higher-than-normal trading volume. However, the recent changes in earnings estimates for the stock do not indicate that this upward trend will continue in the future.